Effects of n-3 polyunsaturated fatty acid on metabolic status in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials

Zhou, Jie; Zuo, Wenting; Tan, Yong; Wang, Xudong; Zhu, Meihong; Zhang, Huili

doi:10.1186/s13048-023-01130-4

Table 2 The effects of n-3 PUFA on insulin resistance indices and lipid profiles based on subgroup analysis

From: Effects of n-3 polyunsaturated fatty acid on metabolic status in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials

	Subgrouped by	No. of trials	No. of participants	Meta-analysis			Heterogeneity
	Subgrouped by	No. of trials	No. of participants	MD	95% CI	p-Value	I² (%)	Cochrane Q-test (p-Value)
BW	Study duration
	≤ 8 weeks	1	61	-1.70	-6.41, 3.01	0.48	NA	NA
	> 8 weeks	5	310	-1.40	-4.56, 1.77	0.39	0	0.92
	Sources
	Marine derived	3	175	-1.07	-4.47, 2.34	0.54	0	0.90
	Plant origins	3	196	-2.11	-6.24, 2.02	0.32	0	0.74
	Dosage
	≤ 1000 mg	2	136	-3.25	-8.29, 1.80	0.21	0	0.89
	> 1000 mg	4	235	-0.84	-3.91, 2.24	0.59	0	0.96
BMI	Study duration
	≤ 8 weeks	2	86	-0.21	-1.71, 1.30	0.79	0	0.97
	> 8 weeks	7	670	-0.61	-1.21, -0.02	0.04	0	0.93
	Sources
	Marine derived	7	460	-0.59	-1.18, -0.00	0.05	0	0.90
	Plant origins	3	196	-0.33	-1.86, 1.21	0.68	0	0.84
	Dosage
	≤ 1000 mg	4	409	-0.54	-1.26, 0.18	0.14	0	1.0
	> 1000 mg	6	347	-0.59	-1.45, 0.28	0.18	0	0.76
WC	Study duration
	≤ 8 weeks	1	61	-0.40	-3.57, 2.77	0.80	NA	NA
	> 8 weeks	2	165	-3.06	-4.19, -1.93	0.00	0	0.87
	Sources
	Marine derived	NA	NA	NA	NA	NA	NA	NA
	Plant origins	NA	NA	NA	NA	NA	NA	NA
	Dosage
	≤ 1000 mg	1	78	-3.50	-9.08, 2.08	0.22	NA	NA
	> 1000 mg	2	148	-2.73	-3.81, -1.65	0.00	58	0.12
FPG	Study duration
	≤ 8 weeks	2	86	-5.79	-10.18, -1.40	0.01	43	0.19
	> 8 weeks	4	269	-3.54	-5.49, -1.59	0.00	17	0.30
	Sources
	Marine derived	4	227	-3.39	-5.47, -1.31	0.00	8	0.35
	Plant origins	2	128	-5.37	-8.84, -1.90	0.00	51	0.15
	Dosage
	≤ 1000 mg	1	68	-7.10	-11.31, -2.89	0.00	NA	NA
	> 1000 mg	5	287	-3.22	-5.18, -1.25	0.00	0	0.47
FINS	Study duration
	≤ 8 weeks	2	86	-1.29	-2.77, 0.20	0.09	0	0.95
	> 8 weeks	4	377	-2.84	-3.69, -1.98	0.00	0	0.85
	Sources
	Marine derived	4	335	-2.40	-3.20, -1.61	0.00	22	0.28
	Plant origins	2	128	-2.75	-4.73, -0.77	0.00	0	0.96
	Dosage
	≤ 1000 mg	2	263	-3.05	-4.06, -2.03	0.00	0	0.79
	> 1000 mg	4	200	-1.77	-2.86, -0.68	0.00	0	0.79
HOMA-IR	Study duration
	≤ 8 weeks	2	86	0.82	-2.19, 3.83	0.59	91	0.00
	> 8 weeks	4	377	-0.47	-0.66, -0.29	0.00	0	0.63
	Sources
	Marine derived	4	335	-0.30	-0.78, 0.17	0.21	74	0.00
	Plant origins	2	128	-0.75	-1.23, -0.27	0.00	0	0.84
	Dosage
	≤ 1000 mg	2	263	-0.43	-0.65, -0.22	0.00	0	0.41
	> 1000 mg	4	200	-0.29	-0.96, 0.37	0.39	76	0.00
QUICKI	Study duration
	≤ 8 weeks	NA	NA	NA	NA	NA	NA	NA
	> 8 weeks	NA	NA	NA	NA	NA	NA	NA
	Sources
	Marine derived	1	54	0.01	0.00, 0.02	0.02	NA	NA
	Plant origins	2	128	0.01	0.01, 0.02	0.00	50	0.16
	Dosage
	≤ 1000 mg	1	68	0.01	0.00, 0.02	0.04	NA	NA
	> 1000 mg	2	114	0.01	0.01, 0.02	0.00	55	0.14
Adiponectin	Study duration
	≤ 8 weeks	1	61	1.50	0.11, 2.89	0.03	NA	NA
	> 8 weeks	2	273	1.46	1.11, 1.81	0.00	0	0.44
	Sources
	Marine derived	NA	NA	NA	NA	NA	NA	NA
	Plant origins	NA	NA	NA	NA	NA	NA	NA
	Dosage
	≤ 1000 mg	2	273	1.46	1.11, 1.81	0.00	0	0.44
	> 1000 mg	1	61	1.50	0.11, 2.89	0.03	NA	NA
TG	Study duration
	≤ 8 weeks	2	86	-5.55	-16.85, 5.74	0.33	21	0.26
	> 8 weeks	5	464	-9.37	-10.61, -8.14	0.00	55	0.06
	Sources
	Marine derived	5	422	-9.28	-10.51, -8.05	0.00	55	0.07
	Plant origins	2	128	-24.94	-48.00, -1.87	0.03	0	0.78
	Dosage
	≤ 1000 mg	2	263	-16.71	-22.50, -10.93	0.00	0	0.47
	> 1000 mg	5	287	-8.98	-10.24, -7.72	0.00	0	0.47
TC	Study duration
	≤ 8 weeks	2	86	-13.42	-26.67, -0.17	0.05	0	0.36
	> 8 weeks	5	464	-12.20	-20.18, -4.22	0.00	79	0.00
	Sources
	Marine derived	5	422	-12.18	-20.45, -3.92	0.00	79	0.00
	Plant origins	2	128	-12.91	-24.77, -1.05	0.03	0	0.33
	Dosage
	≤ 1000 mg	2	263	-20.97	-26.04, -15.90	0.00	0	0.58
	> 1000 mg	5	287	-9.08	-11.55, -6.60	0.00	0	0.65
HDL-C	Study duration
	≤ 8 weeks	2	86	0.64	-2.06, 3.35	0.64	0	0.78
	> 8 weeks	5	464	2.60	0.07, 5.14	0.04	81	0.00
	Sources
	Marine derived	5	422	3.09	0.65, 5.52	0.01	81	0.00
	Plant origins	2	128	-0.65	-4.08, 2.78	0.71	0	0.76
	Dosage
	≤ 1000 mg	2	263	2.27	-3.57, 8.10	0.45	83	0.01
	> 1000 mg	5	287	1.52	-2.30, 5.35	0.43	83	0.00
LDL-C	Study duration
	≤ 8 weeks	2	86	-9.98	-25.36, 5.40	0.20	22	0.26
	> 8 weeks	5	464	-10.86	-21.05, -0.68	0.04	94	0.00
	Sources
	Marine derived	5	422	-11.87	-22.46, -1.28	0.03	94	0.00
	Plant origins	2	128	-6.97	-17.79, 3.86	0.21	0	0.39
	Dosage
	≤ 1000 mg	2	263	-19.45	-34.19, -4.71	0.01	79	0.03
	> 1000 mg	5	287	-9.50	-10.74, -8.27	0.00	1	0.40
VLDL-C	Study duration
	≤ 8 weeks	NA	NA	NA	NA	NA	NA	NA
	> 8 weeks	NA	NA	NA	NA	NA	NA	NA
	Sources
	Marine derived	1	54	1.70	-3.92, 7.32	0.55	NA	NA
	Plant origins	2	128	-5.05	-9.66, -0.44	0.03	0	0.78
	Dosage
	≤ 1000 mg	1	68	-5.60	-11.68, 0.48	0.07	NA	NA
	> 1000 mg	2	114	-0.62	-5.02, 3.78	0.78	41	0.19
hs-CRP	Study duration
	≤ 8 weeks	2	86	0.03	-0.37, 0.43	0.89	0	0.92
	> 8 weeks	4	234	-0.83	-1.69, 0.04	0.06	71	0.02
	Sources
	Marine derived	4	422	-11.87	-22.46, -1.28	0.03	94	0.00
	Plant origins	2	128	-6.97	-17.79, 3.86	0.21	0	0.39
	Dosage
	≤ 1000 mg	1	60	0.20	-0.47, 0.87	0.56	NA	NA
	> 1000 mg	5	260	-0.82	-1.62, -0.02	0.04	68	0.01

Abbreviations: BW body weight, BMI body mass index, FPG fasting plasma glucose, FINS fasting insulin, HDL-C high-density lipoprotein cholesterol, HOMA-IR homeostatic model of assessment for insulin resistance, hs-CRP high sensitivity C-reactive protein, LDL-C low-density lipoprotein cholesterol, QUICK quantitative insulin sensitivity check index, TC total cholesterol, TG triglycerides, VLDL-C very low density lipoprotein-cholesterol, MD mean difference, NA not applicable

Back to article page

ISSN: 1757-2215

Contact us

General enquiries: journalsubmissions@springernature.com

Journal of Ovarian Research

Contact us